Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2005

View Archived Issues

Positive preclinical results for HIV protease inhibitor PPL-100

NTR1: an RVM target for antinociception

Follistatin improves pulmonary fibrosis in rats

ALGRX-4975 induces significant pain relief in patients with Morton's neuroma

Virulizin phase III study results announced

Positive in vitro results for bactericidal antibiotic AR-709

Submission for Zimycan deemed a complete response

Phase II trial begins for Elacyt in malignant melanoma

Galapagos acquires BioFocus

Companies gear up efforts for possible flu pandemic

Dosing begins in phase I study of rFXIII in cardiac surgery patients

Phase I study begins for SEP-225289 for major depressive disorder

Phase III clevidipine safety trials to resume

Financing to support continuation of phase III clinical benefit study of Riquent

Next-generation cephalosporin PPI-0903 begins phase II study

ADT trial of Acapodene reaches target enrollment

Study to investigate if comprehensive antiplatelet therapy prevents heart damage

Biopure updates status of Hemopure development program

Polypill therapy may result promising for NAFLD

ProK-60: a new antiaging product

Snapshots on new products in the treatment of MS

Preliminary phase II data on the safety of erlotinib plus bevacizumab in kidney cancer

Good safety and pharmacokinetic profile of tolvaptan in CHF patients

Recent patents cover novel treatments for psychiatric disorders

Prostanoid EP2 receptor agonists for gynecological disorders claimed in recent Pharmagene patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...